US tariffs threaten one-third of revenue just as domestic policy hands Waaree a cell oligopoly.

• US export channel is under siege. A 123% preliminary anti-dumping duty (April 2026) plus 126% CVD creates a 230%+ tariff wall on direct India-to-US module exports. Roughly 41% of the ₹49,000–60,000 Cr order book is US-tied. A separate CBP investigation (EAPA Case 8163, September 2025) probes whether Waaree mislabeled Chinese-origin cells as Indian — the same supply-chain reconfiguration management is now executing. Final AD determination expected July 2026.
• Domestic cell mandate is the offset the market underweights. India's ALMM cell mandate (June 1, 2026) requires all new solar projects to use domestically manufactured cells. India has 165 GW of module capacity but only 27 GW of qualifying cell capacity — a 6:1 bottleneck. Waaree's 5.4 GW cell line is roughly 20% of that scarce supply. DCR modules already earn 300–350 bps higher margins.
• Both resolve inside 90 days. Q4 FY26 results report today (April 29). ALMM cell mandate enforced June 1. US AD final determination expected July 2026. The stock's next 30% move — up or down — is decided by this window.

From commodity assembler to 25% OPM manufacturer in four years — and the cash backs it up.

OPM expanded from 4% (FY21) to 25% (Q3 FY26) as backward integration into cells cut input costs, DCR mix grew, and scale leverage from 1 GW/month production kicked in. Operating cash flow has exceeded net income in every year — the 3-year CFO/NI of 1.9× confirms earnings are real and cash-backed, not an accrual artifact. The question is whether this margin profile survives the US tariff wall and increased domestic competition from Reliance and Adani post-FY27.

The cell bottleneck is a margin concentrator, not just a policy tailwind.

• Module overcapacity is already here. India has 165 GW of module capacity against 45–50 GW of annual installations (per ICRA). At the module level, this market is oversupplied. Without the cell constraint, module margins would already be compressing.
• Cell scarcity changes the economics. Only 27 GW of ALMM-qualifying cell capacity exists against that 165 GW of modules — a 6:1 ratio. Waaree, Premier Energies, and two or three others control the bottleneck. As US tariffs push Indian manufacturers back to domestic, cell-integrated players gain pricing power while module-only competitors face margin erosion.
• Consensus misframes US risk and domestic protection as additive headwinds. Bears stack US tariff impairment on domestic overcapacity. But US tariffs and the cell mandate are partially offsetting — the domestic cell premium may actually widen as export capacity redirects home. Bear-case floor narrows from ₹2,400 toward ₹2,800–3,000.

CEO churn, ₹25,000 Cr capex into pre-revenue businesses, and a live CBP investigation.

• Two CEO changes in 18 months. Amit Paithankar lasted 20 months before resigning to co-found a startup; CFO Sonal Shrivastava left the same day. Replacement Jignesh Rathod is an 18-year Waaree veteran — continuity preserved, but the simultaneous C-suite exit at peak US controversy is a governance flag.
• ₹25,000+ Cr capex across seven pre-revenue verticals. BESS (20 GWh), electrolysers (1 GW), inverters (4 GW), solar glass, transformers, smart meters, and lithium-ion — all board-approved in seven months, all zero-revenue. FCF turned negative (₹–114 Cr) in FY25; borrowings tripled from ₹553 Cr to ₹2,941 Cr. Management declined to give FY27 EBITDA guidance. Board is considering a QIP/GDR/FCCB fundraise today.
• Forensic risk score: 48 (Elevated). Other income hit ₹576 Cr in FY24 — 37% of operating profit — with ₹364 Cr in Q4 alone, composition undisclosed. CBP probe into cell-origin mislabeling carries retroactive duty exposure. Executive director sits on audit committee.